SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

Search

Almirall SA

Uždarymo kaina

SektoriusSveikatos priežiūra

13.2 1.23

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.86

Max

13.22

Pagrindiniai rodikliai

By Trading Economics

Pajamos

4.1M

13M

Pardavimai

-14M

260M

P/E

Sektoriaus vid.

60.7

77.671

Pelnas, tenkantis vienai akcijai

0.1

Pelno marža

4.811

Darbuotojai

2,026

EBITDA

-23M

54M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+6.6% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-80M

2.6B

Ankstesnė atidarymo kaina

11.97

Ankstesnė uždarymo kaina

13.2

Naujienos nuotaikos

By Acuity

58%

42%

335 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Almirall SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-10 22:02; UTC

Uždarbis

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025-12-10 21:46; UTC

Uždarbis

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025-12-10 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025-12-10 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025-12-10 23:36; UTC

Rinkos pokalbiai

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025-12-10 23:20; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025-12-10 23:15; UTC

Uždarbis

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025-12-10 22:59; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025-12-10 22:45; UTC

Rinkos pokalbiai

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025-12-10 22:40; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 22:06; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 22:02; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:00; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025-12-10 21:53; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025-12-10 21:50; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-10 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 21:33; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025-12-10 21:32; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025-12-10 21:25; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025-12-10 21:16; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025-12-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025-12-10 21:15; UTC

Uždarbis

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Akcijų palyginimas

Kainos pokytis

Almirall SA Prognozė

Kainos tikslas

By TipRanks

6.6% į viršų

12 mėnesių prognozė

Vidutinis 13.9 EUR  6.6%

Aukščiausias 14.5 EUR

Žemiausias 13.3 EUR

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Almirall SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

2

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

9.76 / 10.2Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

335 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat